Alpha 1 Antitrypsin Deficiency Treatment Market – Global Industry Analysis and Forecast 2027 – By Treatment Type, Route of Administration, End User and Region.

Alpha 1 Antitrypsin Deficiency Treatment Market – Global Industry Analysis and Forecast 2027 – By Treatment Type, Route of Administration, End User and Region.

Market Scenario

Alpha 1 Antitrypsin Deficiency Treatment Market was valued US$ XX Mn in 2018 and is expected to reach US$ XX Mn by 2027, at a XX% CAGR of around XX% during a forecast period. Alpha 1 Antitrypsin Deficiency Treatment Market Alpha-1 Antitrypsin (AAT), is a type of protein and it belongs to the class protease inhibitor. This protein is synthesized in the liver and is mainly functions to protect the lungs and liver from the adverse effects of other protein in the body. The AAT deficiency is genetic disorder that leads to low and malfunctioning production of AAT proteins in liver which results in the aggregation of AAT in the liver and low amount of it in blood stream.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The occurrence of AAT deficiency can be diagnosed using genetic tests, blood test, and biopsy tests. Patients with acute AAT deficiency get affected by chronic obstructive pulmonary diseases (COPD), liver cirrhosis, and emphysema diseases. The rate of diagnosis of alpha-1 antitrypsin deficiency across the worldwide is one of the key indicators of the alpha-1 antitrypsin deficiency treatment market. The AAT deficiency disease is treated by diverse therapeutic methods like augmentation therapy, oxygen therapy, bronchodilators, corticosteroids therapy, and other treatment methods. The scope of the report includes a detailed study of global and regional markets for Alpha 1 Antitrypsin Deficiency Treatment with the reasons given for variants in the growth of the industry in certain regions. The upsurge in the occurrences and frequency of respiratory diseases is anticipated to key driving factor for the AAT deficiency market throughout forecast period. AAT deficiency is commonly detected in the North America and European countries which is expected to drive the market. The raising awareness about AAT deficiency disorder in developed countries, technological improvement in the production and purification of Alpha-1 Antitrypsin protein, and government initiatives for raising blood and plasma derived products would increase the growth of AAT deficiency treatment market. The slow diagnosis rates of AAT deficiency and high cost of treatment is expected to hinder growth of AAT deficiency treatment market during forecast period. Apart from this, well-organized distribution network of leading manufacturers are driving the alpha-1 antitrypsin deficiency treatment market growth with a remarkable rate. The report on Alpha 1 Antitrypsin Deficiency Treatment market covers segments such as By Treatment Type, Route of Administration, End User and Region. The Treatment Type segment includes Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, and Others. Among the Treatment Type, Bronchodilator is accounted for the largest XX% market share in the Alpha 1 Antitrypsin Deficiency Treatment market. The Route of Administration segment is further sub-segmented into Parenteral, Inhalations, and Oral. Among the Route of Administration, Inhalations is accounted for the largest XX% market share in the Alpha 1 Antitrypsin Deficiency Treatment market. Based on End User, the Alpha 1 Antitrypsin Deficiency Treatment market is sub-segmented into Specialty Clinics, Hospitals, and Pharmacies. Amongst them Specialty Clinics are accounted for the largest XX% market share in the global Alpha 1 Antitrypsin Deficiency Treatment market. Based on regional segment, the Alpha 1 Antitrypsin Deficiency Treatment market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for a largest share of the global market in 2018, followed by Europe. High occurrence of alpha-1 antitrypsin deficiency between the population of developed countries of the U.S. and Canada, increasing diagnosis rates, high plasma yield, and high per capita health care disbursement are the several key factors resulting the strong demand from North America. Similarly, Europe, which is second most profitable region for the vendors operating in the global alpha-1 antitrypsin deficiency market, is anticipated for the best CAGR among all the regions, display the raising awareness regarding alpha-1 antitrypsin deficiency and high occurrence. Asia Pacic is expected to grow with relatively noteworthy CAGR during 2018-2027, due to the involvement of government in prevention and control of genetic disorders, and development in the diagnostic techniques for critical diseases. Key players operating in the Alpha 1 Antitrypsin Deficiency Treatment market are Pfizer, Baxter, AstraZeneca, Grifols S.A., Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd., Shire plc., LFB Biomedicaments, Abeona Therapeutics, Biogen, Applied Genetic Technologies, Baxalta, Arrowhead Research Corporation, ProBioGen, Chiesi Pharmaceuticals, Curaxys, ProMetic Life Sciences, GlaxoSmithKline Plc., and CSL Behring LLC. GlaxoSmithKline plc received US$ 6.6 Mn from Tres Cantos Open Lab Foundation (TCOLF) for innovation and research on diseases impacting the developing world in September 2018. Additionally, Pfizer, Inc. partnered with GlaxoSmithKline plc to form a joint venture to create the world’s largest over-the-counter (OTC) business, in August 2018. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Alpha 1 Antitrypsin Deficiency Treatment market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Alpha 1 Antitrypsin Deficiency Treatment market.

Scope of the Alpha 1 Antitrypsin Deficiency Treatment Market

Alpha 1 Antitrypsin Deficiency Treatment Market, By Treatment Type

• Augmentation Therapy • Bronchodilator • Corticosteroids • Oxygen Therapy • Others

Alpha 1 Antitrypsin Deficiency Treatment Market, By Route of Administration

• Parenteral • Inhalations • Oral

Alpha 1 Antitrypsin Deficiency Treatment Market, By End User

• Specialty Clinics • Hospitals • Pharmacies

Alpha 1 Antitrypsin Deficiency Treatment Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Alpha 1 Antitrypsin Deficiency Treatment Market

• Pfizer • Baxter • AstraZeneca • Grifols S.A. • Teva Pharmaceutical Industries • Boehringer Ingelheim • Kamada Ltd. • Shire plc. • LFB Biomedicaments • Abeona Therapeutics • Biogen • Applied Genetic Technologies • Baxalta • Arrowhead Research Corporation • ProBioGen • Chiesi Pharmaceuticals • Curaxys • ProMetic Life Sciences • GlaxoSmithKline Plc. • CSL Behring LLC.

Table of Contents

Alpha 1 Antitrypsin Deficiency Treatment Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast 6.1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast, By Treatment Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Treatment Type 7.4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, By Treatment Type 7.5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, By Treatment Type 7.6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, By Treatment Type 8. Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast, By Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Route of Administration 8.4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, By Route of Administration 8.5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, By Route of Administration 8.6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, By Route of Administration 9. Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast, By End User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By End User 9.4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, By End User 9.5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, By End User 9.6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, By End User 10. Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, by Region 10.1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region 10.2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Region 10.3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region 11. North America Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 11.1. Key Findings 11.2. North America Alpha 1 Antitrypsin Deficiency Treatment Market Overview 11.3. North America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Treatment Type 11.4. North America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 11.4.1. Augmentation Therapy 11.4.2. Bronchodilator 11.4.3. Corticosteroids 11.4.4. Oxygen Therapy 11.4.5. Others 11.5. North America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Route of Administration 11.6. North America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 11.6.1. Parenteral 11.6.2. Inhalations 11.6.3. Oral 11.7. North America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By End User 11.8. North America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 11.8.1. Specialty Clinics 11.8.2. Hospitals 11.8.3. Pharmacies 11.9. North America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country 11.10. North America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, by Country 11.12. U.S. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 11.12.1. Augmentation Therapy 11.12.2. Bronchodilator 11.12.3. Corticosteroids 11.12.4. Oxygen Therapy 11.12.5. Others 11.13. U.S. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 11.13.1. Parenteral 11.13.2. Inhalations 11.13.3. Oral 11.14. U.S. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 11.14.1. Specialty Clinics 11.14.2. Hospitals 11.14.3. Pharmacies 11.15. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 11.15.1. Augmentation Therapy 11.15.2. Bronchodilator 11.15.3. Corticosteroids 11.15.4. Oxygen Therapy 11.15.5. Others 11.16. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 11.16.1. Parenteral 11.16.2. Inhalations 11.16.3. Oral 11.17. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 11.17.1. Specialty Clinics 11.17.2. Hospitals 11.17.3. Pharmacies 11.18. North America Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis 11.18.1. By Treatment Type 11.18.2. By Route of Administration 11.18.3. By End User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 12.1. Key Findings 12.2. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Overview 12.3. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Treatment Type 12.4. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.4.1. Augmentation Therapy 12.4.2. Bronchodilator 12.4.3. Corticosteroids 12.4.4. Oxygen Therapy 12.4.5. Others 12.5. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Route of Administration 12.6. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.6.1. Parenteral 12.6.2. Inhalations 12.6.3. Oral 12.7. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By End User 12.8. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.8.1. Specialty Clinics 12.8.2. Hospitals 12.8.3. Pharmacies 12.9. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country 12.10. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, by Country 12.12. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.12.1. Augmentation Therapy 12.12.2. Bronchodilator 12.12.3. Corticosteroids 12.12.4. Oxygen Therapy 12.12.5. Others 12.13. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.13.1. Parenteral 12.13.2. Inhalations 12.13.3. Oral 12.14. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.14.1. Specialty Clinics 12.14.2. Hospitals 12.14.3. Pharmacies 12.15. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.15.1. Augmentation Therapy 12.15.2. Bronchodilator 12.15.3. Corticosteroids 12.15.4. Oxygen Therapy 12.15.5. Others 12.16. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.16.1. Parenteral 12.16.2. Inhalations 12.16.3. Oral 12.17. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.17.1. Specialty Clinics 12.17.2. Hospitals 12.17.3. Pharmacies 12.18. France Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.18.1. Augmentation Therapy 12.18.2. Bronchodilator 12.18.3. Corticosteroids 12.18.4. Oxygen Therapy 12.18.5. Others 12.19. France Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.19.1. Parenteral 12.19.2. Inhalations 12.19.3. Oral 12.20. France Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.20.1. Specialty Clinics 12.20.2. Hospitals 12.20.3. Pharmacies 12.21. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.21.1. Augmentation Therapy 12.21.2. Bronchodilator 12.21.3. Corticosteroids 12.21.4. Oxygen Therapy 12.21.5. Others 12.22. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.22.1. Parenteral 12.22.2. Inhalations 12.22.3. Oral 12.23. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.23.1. Specialty Clinics 12.23.2. Hospitals 12.23.3. Pharmacies 12.24. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.24.1. Augmentation Therapy 12.24.2. Bronchodilator 12.24.3. Corticosteroids 12.24.4. Oxygen Therapy 12.24.5. Others 12.25. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.25.1. Parenteral 12.25.2. Inhalations 12.25.3. Oral 12.26. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.26.1. Specialty Clinics 12.26.2. Hospitals 12.26.3. Pharmacies 12.27. Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 12.27.1. Augmentation Therapy 12.27.2. Bronchodilator 12.27.3. Corticosteroids 12.27.4. Oxygen Therapy 12.27.5. Others 12.28. Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 12.28.1. Parenteral 12.28.2. Inhalations 12.28.3. Oral 12.29. Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 12.29.1. Specialty Clinics 12.29.2. Hospitals 12.29.3. Pharmacies 12.30. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis 12.30.1. By Treatment Type 12.30.2. By Route of Administration 12.30.3. By End User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Overview 13.3. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Treatment Type 13.4. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 13.4.1. Augmentation Therapy 13.4.2. Bronchodilator 13.4.3. Corticosteroids 13.4.4. Oxygen Therapy 13.4.5. Others 13.5. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Route of Administration 13.6. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 13.6.1. Parenteral 13.6.2. Inhalations 13.6.3. Oral 13.7. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By End User 13.8. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 13.8.1. Specialty Clinics 13.8.2. Hospitals 13.8.3. Pharmacies 13.9. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, by Country 13.12. China Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 13.12.1. Augmentation Therapy 13.12.2. Bronchodilator 13.12.3. Corticosteroids 13.12.4. Oxygen Therapy 13.12.5. Others 13.13. China Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 13.13.1. Parenteral 13.13.2. Inhalations 13.13.3. Oral 13.14. China Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 13.14.1. Specialty Clinics 13.14.2. Hospitals 13.14.3. Pharmacies 13.15. India Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 13.15.1. Augmentation Therapy 13.15.2. Bronchodilator 13.15.3. Corticosteroids 13.15.4. Oxygen Therapy 13.15.5. Others 13.16. India Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 13.16.1. Parenteral 13.16.2. Inhalations 13.16.3. Oral 13.17. India Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 13.17.1. Specialty Clinics 13.17.2. Hospitals 13.17.3. Pharmacies 13.18. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 13.18.1. Augmentation Therapy 13.18.2. Bronchodilator 13.18.3. Corticosteroids 13.18.4. Oxygen Therapy 13.18.5. Others 13.19. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 13.19.1. Parenteral 13.19.2. Inhalations 13.19.3. Oral 13.20. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 13.20.1. Specialty Clinics 13.20.2. Hospitals 13.20.3. Pharmacies 13.21. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 13.21.1. Augmentation Therapy 13.21.2. Bronchodilator 13.21.3. Corticosteroids 13.21.4. Oxygen Therapy 13.21.5. Others 13.22. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 13.22.1. Parenteral 13.22.2. Inhalations 13.22.3. Oral 13.23. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 13.23.1. Specialty Clinics 13.23.2. Hospitals 13.23.3. Pharmacies 13.24. Rest of Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 13.24.1. Augmentation Therapy 13.24.2. Bronchodilator 13.24.3. Corticosteroids 13.24.4. Oxygen Therapy 13.24.5. Others 13.25. Rest of Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 13.25.1. Parenteral 13.25.2. Inhalations 13.25.3. Oral 13.26. Rest of Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 13.26.1. Specialty Clinics 13.26.2. Hospitals 13.26.3. Pharmacies 13.27. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis 13.27.1. By Treatment Type 13.27.2. By Route of Administration 13.27.3. By End User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Overview 14.3. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Treatment Type 14.4. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 14.4.1. Augmentation Therapy 14.4.2. Bronchodilator 14.4.3. Corticosteroids 14.4.4. Oxygen Therapy 14.4.5. Others 14.5. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Route of Administration 14.6. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 14.6.1. Parenteral 14.6.2. Inhalations 14.6.3. Oral 14.7. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By End User 14.8. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 14.8.1. Specialty Clinics 14.8.2. Hospitals 14.8.3. Pharmacies 14.9. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, by Country 14.12. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 14.12.1. Augmentation Therapy 14.12.2. Bronchodilator 14.12.3. Corticosteroids 14.12.4. Oxygen Therapy 14.12.5. Others 14.13. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 14.13.1. Parenteral 14.13.2. Inhalations 14.13.3. Oral 14.14. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 14.14.1. Specialty Clinics 14.14.2. Hospitals 14.14.3. Pharmacies 14.15. South Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 14.15.1. Augmentation Therapy 14.15.2. Bronchodilator 14.15.3. Corticosteroids 14.15.4. Oxygen Therapy 14.15.5. Others 14.16. South Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 14.16.1. Parenteral 14.16.2. Inhalations 14.16.3. Oral 14.17. South Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 14.17.1. Specialty Clinics 14.17.2. Hospitals 14.17.3. Pharmacies 14.18. Rest of Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 14.18.1. Augmentation Therapy 14.18.2. Bronchodilator 14.18.3. Corticosteroids 14.18.4. Oxygen Therapy 14.18.5. Others 14.19. Rest of Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 14.19.1. Parenteral 14.19.2. Inhalations 14.19.3. Oral 14.20. Rest of Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 14.20.1. Specialty Clinics 14.20.2. Hospitals 14.20.3. Pharmacies 14.21. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis 14.21.1. By Treatment Type 14.21.2. By Route of Administration 14.21.3. By End User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 15.1. Key Findings 15.2. South America Alpha 1 Antitrypsin Deficiency Treatment Market Overview 15.3. South America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Treatment Type 15.4. South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 15.4.1. Augmentation Therapy 15.4.2. Bronchodilator 15.4.3. Corticosteroids 15.4.4. Oxygen Therapy 15.4.5. Others 15.5. South America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By Route of Administration 15.6. South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 15.6.1. Parenteral 15.6.2. Inhalations 15.6.3. Oral 15.7. South America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, By End User 15.8. South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 15.8.1. Specialty Clinics 15.8.2. Hospitals 15.8.3. Pharmacies 15.9. South America Alpha 1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country 15.10. South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Alpha 1 Antitrypsin Deficiency Treatment Market Analysis, by Country 15.12. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 15.12.1. Augmentation Therapy 15.12.2. Bronchodilator 15.12.3. Corticosteroids 15.12.4. Oxygen Therapy 15.12.5. Others 15.13. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 15.13.1. Parenteral 15.13.2. Inhalations 15.13.3. Oral 15.14. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 15.14.1. Specialty Clinics 15.14.2. Hospitals 15.14.3. Pharmacies 15.15. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 15.15.1. Augmentation Therapy 15.15.2. Bronchodilator 15.15.3. Corticosteroids 15.15.4. Oxygen Therapy 15.15.5. Others 15.16. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 15.16.1. Parenteral 15.16.2. Inhalations 15.16.3. Oral 15.17. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 15.17.1. Specialty Clinics 15.17.2. Hospitals 15.17.3. Pharmacies 15.18. Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Treatment Type 15.18.1. Augmentation Therapy 15.18.2. Bronchodilator 15.18.3. Corticosteroids 15.18.4. Oxygen Therapy 15.18.5. Others 15.19. Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By Route of Administration 15.19.1. Parenteral 15.19.2. Inhalations 15.19.3. Oral 15.20. Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast, By End User 15.20.1. Specialty Clinics 15.20.2. Hospitals 15.20.3. Pharmacies 15.21. South America Alpha 1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis 15.21.1. By Treatment Type 15.21.2. By Route of Administration 15.21.3. By End User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Route of Administrations and R&D investment 16.2.2. New Treatment Center Launches and Treatment Center Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Route of Administrations 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Treatment Center Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Baxter 16.3.3. AstraZeneca 16.3.4. Grifols S.A. 16.3.5. Teva Pharmaceutical Industries 16.3.6. Boehringer Ingelheim 16.3.7. Kamada Ltd. 16.3.8. Shire plc. 16.3.9. LFB Biomedicaments 16.3.10. Abeona Therapeutics 16.3.11. Biogen 16.3.12. Applied Genetic Technologies 16.3.13. Baxalta 16.3.14. Arrowhead Research Corporation 16.3.15. ProBioGen 16.3.16. Chiesi Pharmaceuticals 16.3.17. Curaxys 16.3.18. ProMetic Life Sciences 16.3.19. GlaxoSmithKline Plc. 16.3.20. CSL Behring LLC. 17. Primary Key Insights

About This Report

Report ID37232
Category Healthcare
Published Date
No of Pages178
Contact Us